Science Policy: Anxiety and Resolve at AAAS Conference

A panel discussion on channeling science into policy served as a forum for debating the role of scientists under the current administration.

Written byBen Andrew Henry
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

UCS panel at the AAAS annual meeting in Boston (left to right: Gretchen Goldman, John Holdren, Jane Lubchenco, Lewis Branscomb, Amy Luers, Andrew Rosenberg)BEN ANDREW HENRYFifteen minutes before a panel discussion entitled “Defending Science and Scientific Integrity in the Age of Trump,” listeners had already filled the rows of seats; newcomers stood shoulder to shoulder against the back wall or sat cross-legged in the walkways. The discussion, held Saturday (February 18) and organized by the Union of Concerned Scientists (UCS), was one of the more overtly political events during last week’s American Association for the Advancement of Science (AAAS) 2017 Annual Meeting in Boston, the theme of which was “Serving Society Through Science Policy.”

During the UCS panel on Saturday, the mood of the crowd—which erupted occasionally into cheers—reflected a political energy that enlivened the conference, coming on the heels of a tumultuous first month for the administration of President Donald Trump.

The panel began by enumerating the threats that scientists and science advocates believe could be coming their way during the next four to eight years.

John Holdren, chief science advisor to former President Barack Obama and former director of the White House Office of Science and Technology Policy, said that President Trump’s interest in expensive projects, combined with his promises to lower taxes would likely require slashing research funding in order to balance the books.

“When discretionary spending is threatened, R&D tends to be the first to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies